TSE:APS

5.22
0.43 (8.98%) 1d
0
PARTIAL BUY
Don't get scared of parabolic moves. The chart looks very good. It has shot up in the last 6 weeks. Its next move could be just under $6 pretty quickly. Relative strength vs. the S&P looks very good. However, expect volatility. Own a small holding.
RISKY

An old story, but re-invigorated by an impressive management team. Speculative. Recent sell off in biotech has not helped them.

SELL
At this point, it's a lottery ticket, so for a conservative, fundamental investor, he would call it a sell. Their therapy for pancreatic cancer hasn't been shown to be effective. Be very, very cautious over the next couple of months because it's an orphan stock and you are going into tax loss selling.
BUY
A very interesting company. Has always been a bit of a disappointment. Once they get their FDA approval then the stock should go.
BUY
One of the more undervalued of the biotech's. Have a number of interesting products that are being developed. Has been disappointed in the stock performance. Need some news that will push the valuation.
DON'T BUY
Have done well getting approvals on their products but the stock hasn't done very much. Would like to get rid of his holdings, but not at this price.
WEAK BUY
Not their favorite biotech. Cancer Institute has given them a lot of money for phase two studies. Possibly have a very elegant solution. Expect there will be a lot of news as phase two trials proceed. Volatile. Early stages so only buy a little.
DON'T BUY
Highly speculative. A very high number of shares outstanding. Trading below its 50/200 day moving average. Struggling to hold on to its current level. Have had 10 quarters of losses.
BUY
A very interesting stock at this price. Good cancer drugs. Still awaiting trial completions in the US. Also have new products.
BUY
Getting a lot of patent approvals. A growth story in the making. Have an extensive profile. Have recently flushed out their balance sheets with an issue. A very interesting story, but can be somewhat volatile.
DON'T BUY
High-risk company.You should own five or six in this sector in order to spread the risks.
BUY ON WEAKNESS
Charts indicate a risky stock. If you want to buy, pick a point 10/15% below its recent low.
BUY
Just did a financing to extend development on new products. Sees further improvement.
DON'T BUY
Has never generated any degree of profitability. Speculative.
BUY
Received patent approval on one of their processes. New drugs for cancer are being tested in Mexico and USA. You have to keep an eye on this one.
Showing 1 to 15 of 44 entries

Aptose Biosciences(APS-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Aptose Biosciences is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Aptose Biosciences(APS-T) Frequently Asked Questions

What is Aptose Biosciences stock symbol?

Aptose Biosciences is a Canadian stock, trading under the symbol APS-T on the Toronto Stock Exchange (APS-CT). It is usually referred to as TSX:APS or APS-T

Is Aptose Biosciences a buy or a sell?

In the last year, there was no coverage of Aptose Biosciences published on Stockchase.

Is Aptose Biosciences a good investment or a top pick?

Aptose Biosciences was recommended as a Top Pick by on . Read the latest stock experts ratings for Aptose Biosciences.

Why is Aptose Biosciences stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Aptose Biosciences worth watching?

0 stock analysts on Stockchase covered Aptose Biosciences In the last year. It is a trending stock that is worth watching.

What is Aptose Biosciences stock price?

On 2025-03-13, Aptose Biosciences (APS-T) stock closed at a price of $5.22.